bioAffinity Technologies earnings release, August 7, 2026

bioAffinity Technologies, Inc. (BIAF) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1 bioAffinity

Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

CyPath

Lung test volume increased 216% year over year in Q2 2026

Company drives physician adoption of CyPath Lung and advances longitudinal clinical trial

Pipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeutics

SAN

ANTONIO, Texas – August 7, 2026 – bioAffinity Technologies, Inc.

(Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases and topically delivered therapeutics for squamous and basal cell skin cancers, today reported financial results and business highlights for the quarter ended June 30, 2026.

Q2

2026 Highlights and Recent Events

Management

Commentary

“Our commercial strategy continues to gain significant traction as physicians increasingly recognize the clinical value of CyPath Lung for evaluating patients at high risk for lung cancer and surveilling lung cancer survivors for recurrence,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “During the second quarter, CyPath Lung test volume surged 216% year-over-year.

This growth reflects accelerating physician adoption and clinical confidence in our technology. As more clinics integrate CyPath Lung into their standard of care workflows, peer-to-peer education is a powerful driving force behind building broader awareness of the test’s ability to provide objective data that complements traditional imaging and supports faster, more informed clinical decisions.”

Ms.

Zannes continued, “Alongside our commercial momentum, we achieved critical milestones across our strategic roadmap. In the second quarter, we expanded physician education initiatives, including scientific presentations, webinars, podcasts and real-world clinical case studies. We continued to make progress in our large-scale longitudinal study that includes VA and military medical centers, expanding our outreach to veterans. By leveraging our expertise in flow cytometry and AI and our work with siRNAs, we are building a robust pipeline of precision diagnostics for the large asthma and COPD markets and even larger therapeutic markets for topically delivered drugs that treat squamous and basal cell skin cancers.”

Ms.

Zannes concluded, “Looking ahead, our priorities for the second half of 2026 are expanding physician adoption, increasing utilization among existing customers, and introducing CyPath Lung to new healthcare systems and specialty practices, including oncology. The positive results we see from research and development of precision diagnostics and a therapeutic for skin cancers are exciting as we advance our pipeline. We believe this balanced approach positions bioAffinity to create lasting value for patients, healthcare providers and shareholders.”

Second

Quarter 2026 Financial Results

Revenue for the quarter ended June 30, 2026, was $1.5 million, a 19% increase from the $1.3 million reported for the same period in 2025. The increase is primarily due to an increase in sales of CyPath Lung.

Operating expenses for the second quarter of 2026 were $4.8 million, compared with $3.8 million in the second quarter of 2025.

Net loss for the quarter ended June 30, 2026, was $3.4 million, compared with a net loss of $4.1 million for the second quarter of 2025.

Cash and cash equivalents as of June 30, 2026, were $2.4 million, compared with $6.4 million as of December 31, 2025.

About

CyPath Lung

CyPath

Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity,

88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath Lung is marketed as a Laboratory Developed

Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.

About bioAffinity Technologies, Inc. bioAffinity

Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision

Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement

Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — Unaudited Condensed Consolidated Statements of Operations

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue1,510,5791,269,4832,862,1063,123,080
Operating expenses:Direct costs and expenses1,087,8371,016,6022,016,4732,384,462
Operating expenses:Research and development361,575311,372711,282678,758
Operating expenses:Clinical development475,885129,279809,925267,632
Operating expenses:Selling, general and administrative2,858,5902,214,5616,100,1924,667,110
Operating expenses:Depreciation and amortization61,556113,229176,074267,817
Operating expenses:Total operating expenses4,845,4433,785,0439,813,9468,265,779
Operating expenses:Loss from operations-3,334,864-2,515,560-6,951,840-5,142,699
Other income (expense):Interest income3,3582,02513,3842,567
Other income (expense):Interest expense-11,688-10,460-26,410-25,945
Other income (expense):Other income4,73838,0533,37238,055
Other income (expense):Other expense-27,626-483,043-35,198-492,685
Other income (expense):Change in fair value of warrants issued-1,062,818-1,062,818
Other income (expense):Total other income (expense), net-31,218-1,516,243-44,852-1,540,826
Other income (expense):Net loss before provision for income tax expense-3,366,082-4,031,803-6,996,692-6,683,525
Other income (expense):Income tax expense28,98437,679
Other income (expense):Net loss-3,366,082-4,060,787-6,996,692-6,721,204
Other income (expense):Net loss per common share, basic and diluted-0.64-5.07-1.44-10.01
Other income (expense):Weighted average common shares outstanding5,226,753800,6374,860,753671,529

Balance Sheet

June 30, 2026 — Condensed Consolidated Balance Sheets

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents2,429,7196,449,782
Current assets:Accounts and other receivables, net894,823541,962
Current assets:Inventory82,37853,548
Current assets:Prepaid expenses and other current assets458,360519,916
Current assets:Total current assets3,865,2807,565,208
Non-current assets:Property and equipment, net313,708265,593
Non-current assets:Operating lease right-of-use asset, net769,270334,289
Non-current assets:Finance lease right-of-use asset, net562,187661,575
Non-current assets:Goodwill1,404,4861,404,486
Non-current assets:Intangible assets, net687,639716,806
Non-current assets:Other assets16,70912,815
Non-current assets:Total assets7,619,27910,960,772
Current liabilities:Accounts payable969,845761,901
Current liabilities:Accrued expenses1,414,4921,717,989
Current liabilities:Unearned revenue31,14042,405
Current liabilities:Operating lease liability, current portion163,276139,220
Current liabilities:Finance lease liability, current portion79,592139,490
Current liabilities:Notes payable, current portion22,561105,161
Current liabilities:Total current liabilities2,680,9062,906,166
Non-current liabilities:Operating lease liability, net of current portion637,643202,878
Non-current liabilities:Finance lease liability, net of current portion495,468532,759
Non-current liabilities:Notes payable, net of current portion36,46541,313
Non-current liabilities:Total liabilities3,850,4823,683,116
Stockholders’ equity:Preferred Stock, par value $0.001 per share; 20,000,000 shares authorized; 450 shares and 700 shares issued and outstanding at June 30, 2026, and December 31, 2025, respectively11
Stockholders’ equity:Common Stock, par value $0.007 per share; 350,000,000 shares authorized; 6,783,061 and 4,498,675 issued and outstanding at June 30, 2026, and December 31, 2025, respectively47,45431,461
Stockholders’ equity:Additional paid-in capital79,272,09875,800,258
Stockholders’ equity:Accumulated deficit-75,550,756-68,554,064
Stockholders’ equity:Total stockholders’ equity3,768,7977,277,656
Stockholders’ equity:Total liabilities and stockholders’ equity7,619,27910,960,772
Full release

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.

Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”

“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”

“plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are... (truncking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully commercialize CyPath Lung and achieve broader market acceptance, the Company’s ability to obtain adequate financing to fund operations and development activities, risks related to the results of clinical trials and studies, the Company’s ability to obtain and maintain regulatory approvals or clearances, the Company’s ability to protect its intellectual property, competition from other companies developing similar products, changes in applicable laws or regulations, the

Company’s limited operating history and history of operating losses, the Company’s receipt of a delisting determination notice from the Nasdaq Stock Market and the risks and uncertainties associated with the Company’s intent to appeal such determination and the outcome of any such appeal, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended

December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Contact bioAffinity

Technologies

Julie Anne Overton

Director of Communications investors@bioaffinitytech.com bioAffinity

Technologies, Inc.

Condensed

Consolidated Balance Sheets bioAffinity

Technologies, Inc.

Unaudited

Condensed Consolidated Statements of Operations

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · bioAffinity Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.